Comparison of the effects of escitalopram and nortriptyline on painful symptoms in patients with major depression

General Hospital Psychiatry

Volumn 37, Issue 1, 2015, Pages 36-39

  Jaracz, Jan ^a   Gattner, Karolina ^a   Moczko, Jerzy ^a   Hauser, Joanna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Escitalopram; Major depression; Nortriptyline; Pain

Indexed keywords

ESCITALOPRAM; NORTRIPTYLINE; ADRENERGIC RECEPTOR AFFECTING AGENT; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DSM-IV; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; ICD-10-PCS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PAIN INTENSITY; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; COMPARATIVE STUDY; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; PAIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84922683701     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2014.10.005     Document Type: Article

References (33)

1. Bair M.J., Robinson R.L., Katon W., Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003, 163:2433-2445.
2. Husain M.M., Rush A.J., Trivedi M.H., McClintock S.M., Wisniewski S.R., Davis L., et al. Pain in depression: STAR*D study findings. J Psychosom Res 2007, 63:113-122.
3. Agüera-Ortiz L., Failde I., Mico J.A., Cervilla J., López-Ibor J.J. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. J Affect Disord 2011, 130:106-112.
4. Demyttenaere K., Reed C., Quail D., Bauer M., Dantchev N., Montejo A.L., et al. Presence and predictors of pain in depression: results from the FINDER study. J Affect Disord 2010, 125:53-60.
5. Karp J.F., Scott J., Houck P., Reynolds C.F., Kupfer D.J., Frank E. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005, 66:591-597.
6. Von Korff M., Ormel J., Katon W., Lin E.H. Disability and depression among high utilizers of health care: a longitudinal analysis. Arch Gen Psychiatry 1992, 49:91-100.
7. Bair M.J., Robinson R.L., Eckert G.J., Stang P.E., Croghan T.W., Kroenke K. Impact of pain on depression treatment response in primary care. Psychosom Med 2004, 66:17-22.
8. Stahl S., Briley M. Understanding pain in depression. Hum Psychopharmacol 2004, 19(Suppl. 1):S9-S13.
9. Sindrup S.H., Bach F.W., Madsen C., Gram L.F., Jensen T.S. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003, 60:1284-1289.
10. Bradley R.H., Barkin R.L., Jerome J., DeYoung K., Dodge C.W. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003, 10:318-323.
11. Vitton O., Gendreau M., Gendreau J., Kranzler J., Rao S.G. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004, 19(Suppl. 1):S27-S35.
12. Clauw D.J., Mease P., Palmer R.H., Gendreau R.M., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30:1988-2004.
13. Arnold L.M., Clauw D.J., Wohlreich M.M., Wang F., Ahl J., Gaynor P.J., et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009, 11:237-244.
14. Fava M., Mallinckrodt C.H., Detke M.J., Watkin J.G., Wohlreich M.M. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry 2004, 65:521-530.
15. Brannan S.K., Mallinckrodt C.H., Brown E.B., Wohlreich M.M., Watkin J.G., Schatzberg A.F. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005, 39:43-53.
16. Raskin J., Wiltse C.G., Siegal A., Sheikh J., Xu J., Dinkel J.J., et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo- controlled trial. Am J Psychiatry 2007, 164:900-909.
17. Goldstein D.J., Lu Y., Detke M.J., Hudson J., Iyengar S., Demitrack M.A. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004, 45:17-28.
18. Keers R., Uher R., Gupta B., Rietschel M., Schulze T.G., Hauser J., et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J Affect Disord 2010, 127:337-342.
19. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009, 9:225-233.
20. Uher R., Perroud N., Ng M.Y., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010, 167:555-564.
21. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Clin Psychol 1967, 6:278-296.
23. Beck A.T., Ward C.H., Mandelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
24. Todd K.H., Funk J.P. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 1996, 3:142-146.
25. Uher R., Maier W., Hauser J., Marusic A., Schmael C., Mors O., et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009, 194:252-259.
26. Hegerl U., Mergl R., Quail D., Schneider E., Hundemer H.P., Linden M. Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine?. Pharmacopsychiatry 2012, 45:114-118.
27. Marangell L.B., Clauw D.J., Choy E., Wang F., Shoemaker S., Bradley L., et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011, 152:31-37.
28. Suehiro K., Funao T., Fujimoto Y., Yamada T., Mori T., Nishikawa K. Relationship between noradrenaline release in the locus coeruleus and antiallodynic efficacy of analgesics in rats with painful diabetic neuropathy. Life Sci 2013, 92:1138-1144.
29. Nakajima K., Obata H., Iriuchijima N., Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain 2012, 153:990-997.
30. Hartrick C.T., Rozek R.J. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011, 25:359-370.
31. Masand P.S., Narasimhan M., Patkar A.A. Paroxetine for somatic pain associated with physical illness: a review. Prim Care Companion J Clin Psychiatry 2006, 8:122-130.
32. Muller J.E., Wentzel I., Koen L., Niehaus D.J., Seedat S., Stein D.J. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2008, 23:43-48.
33. Mazza M., Mazza O., Pazzaglia C., Padua L., Mazza S. Escitalopram 20mg versus duloxetine 60mg for the treatment of chronic low back pain. Expert Opin Pharmacother 2010, 11:1049-1052.